Merge Talks Between The EVERY Co and Onego Bio
Alt-egg startups The EVERY Company and Onego Bio were discussing a merger to create a new company with a valuation of $400m before talks fell apart.
The EVERY Co has urged a court in Wisconsin to dismiss a lawsuit from Onego Bio seeking to invalidate one of EVERY's patents.
Patent Dispute
The dispute centers on whether Onego is infringing a “foundational” patent from The EVERY Co covering ovalbumin expression in a range of hosts.
- The EVERY Co uses yeast (Komagataella phaffii) as its host microorganism.
- Onego Bio uses fungus (Trichoderma reesei).
No comment from companies
Author summary: Merger talks failed due to IP issues.
More News
- Added value for tenants: Simple improvements that can justify higher rent - PropertyWire
- How Gratitude Journal Boosts Mental Well-Being in Employees
- President Aliyev’s reconstruction strategy reshapes liberated lands into engines of growth
- ANZ flags $1.1b hit; Atlassian CFO exits; From prince to pauper
- Diversity Makes Us Realize We Hate Each Other
- Quick start, steady goaltending propel Sharks to first home win of season
- Billie Eilish Calls on Billionaires to Do More for People in Need
- Opinion: How medical cannabis can help Canada reach its new export ambitions